NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

184.12B

Vuru Grade

69.64/100

Current Price

$77.32
+0.22 (+0.29%)

Growth Price

$56.04
Overvalued by 27.52%

Stability Price

$14.58
Overvalued by 81.15%

Company Metrics

  • P/E 27.57
  • P/S 3.67
  • P/B 2.56
  • EPS 2.8
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.53%
  • Avg. Vol. 2.14M
  • Shares 2.38B
  • Market Cap. 184.12B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
Market Exclusive - Jun 23, 2016
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.
Novartis AG (ADR) (NYSE:NVS) Biosimilars Roadmap
Market Exclusive - Jun 20, 2016
Novartis AG (ADR) (NYSE:NVS) is in the process of tripling its portfolio of biosimilar drugs by 2020. The company is particularly working to develop alternatives to blockbuster drugs such as Johnson & Johnson (NYSE:JNJ) Remicade and Amgen, Inc.
Novartis AG (ADR) Has Enough Arsenal to Steer Clear of Ongoing Rout - Bidness ETC
How Many Novartis AG (ADR) (NYSE:NVS)'s Analysts Are Bearish? - Franklin Independent
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
Business Finance News - Jun 20, 2016
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
Business Finance News - May 20, 2016
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Novartis AG (ADR) First-Quarter Earnings: What to Expect?
Bidness ETC - Apr 20, 2016
Novartis AG (ADR) (NYSE:NVS) is set to announce its financial results for the first quarter of 2016 (1Q) on Thursday, April 21.
Analysts Ratings on Novartis AG (ADR) (NYSE:NVS)
CWRU Observer - Jun 14, 2016
The mean price target for the shares of Novartis AG (ADR) (NYSE:NVS)is at $92.50 while the highest price target suggested by the analysts is $115.00 and low price target is $81.00.
HC Stocks Alerts: Shire PLC (ADR) (NASDAQ:SHPG), Novartis AG (ADR) (NYSE:NVS) - share market updates (press release)
What Analyst's have to say about Novartis AG (ADR) (NYSE:NVS)
CWRU Observer - May 31, 2016
The mean price target for the shares of Novartis AG (ADR) (NYSE:NVS)is at $92.50 while the highest price target suggested by the analysts is $115.00 and low price target is $81.00.
Novartis AG (ADR) Stock Price Gaps Up Today; Buyers Are Thriving
Franklin Independent - Jun 18, 2016
The stock of Novartis AG (ADR) (NYSE:NVS) gapped up by $0.6 today and has $109.07 target or 40.00% above today's $77.91 share price.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Amgen, Novartis Court Case May Ease US Launch of Biosimilars
Bidness ETC - Jun 23, 2016
The first biosimilar to hit the US market was Zarxio, developed by Novartis AG's (ADR) (NYSE:NVS) generic subsidiary Sandoz, to imitate Amgen, Inc.'d (NASDAQ:AMGN) blockbuster cancer drug Neupogen.